论文部分内容阅读
目的观察新辅助化疗对宫颈癌患者细胞及体液免疫功能影响。方法选取该院收治的宫颈癌患者120例。所有患者均为肿瘤直径>4cm的Ⅰb期~Ⅱa期,均进行2个周期辅助化疗,比较治疗前后CD4、CD8细胞的百分率,及调节性T细胞水平。结果治疗前后患者血浆中CD+4、CD+8细胞的百分率及CD+4/CD+8差异无统计学意义(P>0.05)。治疗后患者调节性T细胞/CD+4细胞的比值较治疗前比较明显降低,差异有统计学意义(P<0.05)。治疗后外周血淋巴细胞计数较治疗前下降,差异有统计学意义(P<0.05)。结论新辅助化疗治疗子宫颈癌可降低外周血中参与免疫功能细胞的数量,但可能不改变患者的免疫平衡,化疗刺激有利于患者免疫应答微环境建立。
Objective To observe the effect of neoadjuvant chemotherapy on cellular and humoral immune function in patients with cervical cancer. Methods 120 cases of cervical cancer admitted to our hospital were selected. All patients were stage Ⅰb ~ Ⅱa with tumor diameter> 4cm. Two cycles of adjuvant chemotherapy were performed. The percentage of CD4 and CD8 cells and the level of regulatory T cells before and after treatment were compared. Results There was no significant difference in the percentage of CD + 4, CD + 8 cells and CD + 4 / CD + 8 in plasma before and after treatment (P> 0.05). After treatment, the ratio of regulatory T cells / CD + 4 cells was significantly lower than that before treatment, the difference was statistically significant (P <0.05). After treatment, the peripheral blood lymphocyte count decreased compared with before treatment, the difference was statistically significant (P <0.05). Conclusion Neoadjuvant chemotherapy for cervical cancer can reduce the number of peripheral blood cells involved in immune function, but may not change the patient’s immune balance, chemotherapy is conducive to immune response to patients with micro-environment.